Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

Keyphrases

• Immunomodulatory Effect 100%
• B Lymphocytes 100%
• Immune Parameters 100%
• Ibrutinib 100%
• Acalabrutinib 100%
• BTK Inhibitor 100%
• Chronic Lymphocytic Leukemia 50%
• Adverse Effects 25%
• Cell Subsets 25%
• B Cells 25%
• Homeostasis 25%
• Immune System 25%
• Dendritic Cells 25%
• Signaling Pathway 25%
• T Cells 25%
• Human Disease 25%
• Granulocytes 25%
• Mast Cells 25%
• Immune Dysregulation 25%
• Receptor Signaling 25%
• Treatment Options 25%
• Natural Killer Cells 25%
• Myeloid-derived Suppressor Cells 25%
• Repurposing 25%
• Specific Receptor 25%
• Monocyte-derived Macrophages 25%
• Clinical Efficacy 25%
• B-cell Malignancies 25%
• Platelets 25%
• Differential Effects 25%
• Leukemia Patients 25%
• Osteoclast 25%
• High Efficacy 25%
• Overlapping Effect 25%

Medicine and Dentistry

• Immunocompetent Cell 100%
• B Lymphocyte 100%
• Ibrutinib 100%
• Acalabrutinib 100%
• B Cell 50%
• B-Cell Chronic Lymphocytic Leukemia 50%
• Homeostasis 25%
• Dendritic Cell 25%
• Mast Cell 25%
• Macrophage 25%
• T Cell 25%
• Granulocyte 25%
• Receptor 25%
• Cancer 25%
• Natural Killer Cell 25%
• Platelet 25%
• Osteoclast 25%
• Cell Signaling Pathway 25%
• Immune Dysregulation 25%
• Myeloid-Derived Suppressor Cell 25%
• Immune System 25%
• Diseases 25%
• Adverse Effect 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Ibrutinib 100%
• Acalabrutinib 100%
• Chronic Lymphatic Leukemia 50%
• Immune Dysregulation 25%
• Receptor 25%
• Repurposing 25%
• Diseases 25%